7th January 2008: Scigen Limited (ASX:SIE) announces that it has entered into a Commercialization Agreement with Julphar for the distribution and marketing of Sci-B-Vac, its third generation hepatitis B vaccine in the Middle East, parts of Africa and Asia. The countries include all the Arab speaking countries in addition to Malaysia, Bangladesh, Pakistan and Afghanistan.
In the Middle East where the prevalence of hepatitis B is over 8%, such as in Saudi Arabia, and significantly more in Tropical Africa, the market potential offers great opportunities for Sci-B-Vac. Julphar is committed to aggressively pursue these markets.
Sci-B-Vac was presented to all of Julphar’s delegates and marketing personnel at their annual meeting that took place November 2007 in Dubai and was enthusiastically received.
First commercialization is expected in the first quarter of 2009. This partnership will greatly enhance SciGen’s global marketing penetration of Sci-B-Vac and pave the way for stronger partnership together with Julphar in the Biotechnology sector.
About SciGen:
SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.
SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.
SciGen’s competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.
SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands.
Add to My Watchlist
What is My Watchlist?